AstraZeneca mulls €240bn mega-merger with Gilead Sciences

Pharma firm AstraZeneca is considering a merger with US peer Gilead Sciences to create a company with a market value of $240bn.

Britain’s AstraZeneca has been considering “the biggest pharmaceuticals deal in history”, says Max Nisen on Bloomberg: merging with US peer Gilead Sciences to create a company with a market value of $240bn. The aim would be to combine AstraZeneca’s “enviable” drug pipeline with Gilead’s profitable HIV drug business, which has given it a “steady cash flow” and “strong balance sheet”.

Advertisement - Article continues below

Any merger with Gilead would be a bad mistake, says Ben Marlow in The Daily Telegraph. Not only is there “overwhelming” evidence that most mega-mergers end up destroying value, but the ongoing travel restrictions also mean that this one could “take several years to be negotiated”. In any case, with AstraZeneca at the forefront of developing a coronavirus vaccine as well as various treatments for those already infected with the disease, it needs to “concentrate on the day job”. The last thing managers should be doing is “wasting time” with “desktop empire-building”.Tentative talks seem to have gone nowhere, says Nils Pratley in The Guardian. Still, the fact that the idea was even broached at all will unnerve shareholders “who thought the future for the next few years was mapped out and rosy”. 

With new cancer drug sales “soaring [and the]cardiovascular and respiratory divisions [ready] to deliver the next round of growth”, AstraZeneca’s CEO Pascal Soriot (pictured) should stick with his current strategy. Instead, he apparently dreams of “signing off in dreaded transformative style” with a deal that could prove “messy and political”.




The British equity market is shrinking

British startups are abandoning public stockmarkets and turning to deep-pocketed Silicon Valley venture capitalists for their investment needs.
8 Nov 2019
Share tips

Three biotech stocks on the cutting edge of medicine

Investors are only now recognising the vast potential of biotech stocks. Here. Professional investor Dr Daniel Koller of BB Biotech AG picks three of …
31 Jul 2019

There are lots of reasons to be bearish – but you should stick with the bulls

There are plenty of reasons to be gloomy about the stockmarkets. But the trend remains up, says Dominic Frisby. And you don’t want to bet against the …
17 Jul 2019

Good news on jobs scares US stockmarkets

June brought the best monthly US jobs growth of the year, but stockmarkets were not best pleased.
11 Jul 2019

Most Popular


The end of the bond bull market and the return of inflation

Central bank stimulus, surging post-lockdown demand and the end of the 40-year bond bull market. It all points to inflation, says John Stepek. Here’s …
30 Jun 2020

This chart pattern could be extraordinarily bullish for gold

The mother of all patterns is developing in the gold charts, says Dominic Frisby. And if everything plays out well, gold could hit a price that invest…
1 Jul 2020
Global Economy

How “pent-up demand” could drive a V-shaped economic recovery

“Pent-up demand” is usually a myth. But not this time. The Covid lockdown has created genuine pent-up demand, says Merryn Somerset Webb. That’s now be…
29 Jun 2020